Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies
| Filename | 245. Zazzali et al., Angioedema omalizumab CIU CSU, AAAI 2016.pdf |
| Filesize | 469.26 KB |
| Version | o.245 |
| Date added | July 30, 2020 |
| Downloaded | 0 times |
| Category | Original Work |
| Authors | Zazzali, J. L., Kaplan, A., Maurer, M. Raimundo, K., Trzaskoma, B., Solari, P. G., Antonova, E., Mendelson, M., and Rosén, K. |
| Citation | Zazzali, J. L., Kaplan, A., Maurer, M. Raimundo, K., Trzaskoma, B., Solari, P. G., Antonova, E., Mendelson, M., and Rosén, K.: Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Ann. Allergy Asthma Immunol. 2016: 117; 370-377. |
| Corresponding authors | Antonova, E. |
| DocNum | O.245 |
| DocType | |
| Edition; Page | 117; 370-377 |
| IF | 3.72 |
| Publisher | Ann. Allergy Asthma Immunol. |
| ReleaseDate | 2016 |
Background: Angioedema, present in some patients with chronic idiopathic/spontaneous urticaria (CIU/CSU), may have a negative effect on patient quality of life.
Objective :To describe patient-reported angioedema and its management in the pivotal omalizumab studies(ASTERIA I, ASTERIA II, GLACIAL).
Methods: Enrolled patients with CIU/CSU remained symptomatic despite treatment with histamine1(H1)-antihistamines at licensed doses (ASTERIA I, ASTERIA II) or H1-antihistamines at up to 4 times the approveddose plus H2-antihistamines and/or a leukotriene receptor antagonist (GLACIAL). All studies administeredomalizumab (75,150, or 300 mg in ASTERIA I and ASTERIA II; 300 mg in GLACIAL) or placebo subcutaneouslyevery 4 weeks for at least 12 weeks. Urticaria Patient Daily Diary entries were completed by patients andsummarized.
Results: At baseline, angioedema prevalence was higher in GLACIAL (53.1%) than in ASTERIA I (47.5%) orASTERIA II (40.7%). The mean proportion of angioedema-free days during weeks 4 to 12 was greater forpatients treated with 300 mg of omalizumab than placebo in ASTERIA I (96.1% vs 88.2%,P<.001), ASTERIA II(95.5% vs 89.2%,P<.001), and GLACIAL (91.0% vs 88.7%,P¼.006). Most patient-reported angioedema wasmanaged by low-intensity interventions (doing nothing or taking medication).
Conclusion: Treatment with 300 mg of omalizumab was efficacious in reducing patient-reported angioe-dema. Low-intensity interventions were generally used to manage angioedema episodes.
Trial Registration: clinicaltrials.govIdentifiers: NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), andNCT01264939 (GLACIAL).
(Last update: 12.2023)
| Number of original publications in peer-reviewed journals: | 580 |
| Number of reviews in peer-reviewed journals: | 210 |
| Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
| Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
| Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
| Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
| Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.